Last reviewed · How we verify

Rosuvastatin Calcium 20 MG, QD

Kuhnil Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Rosuvastatin Calcium 20 MG, QD is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Kuhnil Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.

At a glance

Generic nameRosuvastatin Calcium 20 MG, QD
SponsorKuhnil Pharmaceutical Co., Ltd.
Drug classHMG-CoA reductase inhibitor (statin)
TargetHMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rosuvastatin Calcium 20 MG, QD

What is Rosuvastatin Calcium 20 MG, QD?

Rosuvastatin Calcium 20 MG, QD is a HMG-CoA reductase inhibitor (statin) drug developed by Kuhnil Pharmaceutical Co., Ltd., indicated for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.

How does Rosuvastatin Calcium 20 MG, QD work?

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

What is Rosuvastatin Calcium 20 MG, QD used for?

Rosuvastatin Calcium 20 MG, QD is indicated for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.

Who makes Rosuvastatin Calcium 20 MG, QD?

Rosuvastatin Calcium 20 MG, QD is developed by Kuhnil Pharmaceutical Co., Ltd. (see full Kuhnil Pharmaceutical Co., Ltd. pipeline at /company/kuhnil-pharmaceutical-co-ltd).

What drug class is Rosuvastatin Calcium 20 MG, QD in?

Rosuvastatin Calcium 20 MG, QD belongs to the HMG-CoA reductase inhibitor (statin) class. See all HMG-CoA reductase inhibitor (statin) drugs at /class/hmg-coa-reductase-inhibitor-statin.

What development phase is Rosuvastatin Calcium 20 MG, QD in?

Rosuvastatin Calcium 20 MG, QD is in Phase 3.

What are the side effects of Rosuvastatin Calcium 20 MG, QD?

Common side effects of Rosuvastatin Calcium 20 MG, QD include Myalgia (muscle pain), Elevated liver enzymes (ALT/AST), Headache, Rhabdomyolysis (rare), Nausea.

What does Rosuvastatin Calcium 20 MG, QD target?

Rosuvastatin Calcium 20 MG, QD targets HMG-CoA reductase and is a HMG-CoA reductase inhibitor (statin).

Related